Journal
INTERNAL MEDICINE
Volume 46, Issue 6, Pages 261-266Publisher
JAPAN SOC INTERNAL MEDICINE
DOI: 10.2169/internalmedicine.46.6181
Keywords
gastric cancer; screening; pepsinogen; atrophic gastritis; gastric cancer screening; high-risk group
Categories
Ask authors/readers for more resources
Since the 1990's, the test for serum pepsinogen as a marker for chronic atrophic gastritis has been incorporated into gastric cancer screening programs, on a trial basis, to identify people at high risk for gastric cancer. The addition of the serum test to the cancer screening program has been shown to improve the detection rate of cancer and pepsinogen testing is useful in detecting early-stage gastric cancers arising from atrophic gastric mucosa, which macroscopically tend to be elevated and histologically differentiated. Furthermore, the cost for the detection of a single cancer case is much less than that for conventional screening. Thus, with the introduction of pepsinogen testing, complimenting barium X-ray, a more efficient screening system is available.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available